Northern Swan invests millions in pharma startup Cansativa
FRANKFURT, Germany, Feb. 19, 2019 (GLOBE NEWSWIRE) — Northern Swan, a New-York based investment firm, has invested several million euros in Cansativa GmbH, in order to further accelerate the growth of the company and its integration into the wider European market. Cansativa will use this investment to expand its current facilities to become a “EU GxP Innovation Hub” and fulfillment center for medical cannabis.
This way, Cansativa helps promote the professionalization of the entire medical cannabis industry in Europe from its location in Frankfurt am Main, Germany. The new site will serve as the EU hub for the growing industry, granting pharmaceutical companies from all over the world access to the rapidly growing European market. Cansativa is poised to lend its support as a reliable, independent full-service GxP partner.”
Unlike the majority of our competitors, we operate independently of third-party contractors – Ever since we started the company, we’ve been moving our products through our own warehouse on a daily basis, and we plan to implement each additional process on our own as well.”Jakob Sons, co-founder of Cansativa and joint Managing Director along with Benedikt Sons.
Northern Swan brings much more than money to the table, particularly regarding their unpaired expertise, technical know-how, their professional network, and portfolio companies in the medical cannabis industry. “We’re really confident that Cansativa is the ideal partner with whom to collaborate in order to develop the European market for medicinal cannabis.”Kyle Detwiler, CEO of Northern Swan Holdings.